A Study to Evaluate Atumelnant in Adults With Congenital Adrenal Hyperplasia
← catalyst calendarNCT07144163 · readout ≤ 285 d
Sponsored by Crinetics Pharmaceuticals Inc. (industry) · CRNX — their whole pipeline →.
Phase
Phase 3
Status
Recruiting
Study type
Interventional
Design
Randomized · Triple · Treatment
Enrollment
150estimated
Sites
63
Countries
Argentina, Australia, Austria +11
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-12-11 | actual | When the study began enrolling |
| Primary completion | May 2027 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | May 2027 | estimated | The whole study's end, after follow-up |
| First posted | 2025-08-27 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-12 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Congenital Adrenal Hyperplasia
- Classic Congenital Adrenal Hyperplasia
Interventions
- Drug: Atumelnant — also filed as CRN04894
- Drug: Placebo
Primary outcome
what the primary-completion date above is the date OFProportion of participants with morning post-GC A4 ≤ ULN who are on physiologic GC replacement.
measured Week 32
Permalink · CRNX's whole pipeline · Catalyst calendar · Every registered study · What changed